Focus Taiwan
Date: 2017/03/07
By: Wen Kuei-hsiang and Y.F. Low
Taipei, March 7 (CNA) The Food and Drug Administration (FDA) on Tuesday ordered a
The FDA has requested Crestor’s manufacturer, AstraZeneca, to help replace the counterfeits, and the company will also conduct a comprehensive examination in regional hospitals and medical centers, said FDA Director-General Wu Shou-mei (吳秀梅).
The administration first confirmed on March 4 that batch number MV503 of Crestor 10 mg tablets had been mixed with counterfeits containing atorvastatin, a cheaper lipid-lowering ingredient, instead of rosuvastatin. [FULL STORY]